CXO leading medicine is planned to repurchase 300 million US dollars!Medical ETF (512170) rises more than 2%

CXO leading Yaoming Biological Announcement, the board of directors has decided to use the purchase of repurchase, in order to purchase a shares at a total price of no more than 300 million US dollars (about 2.34 billion Hong Kong dollars) from time to time. The group's actual business prospects, and provide the company with a good opportunity for further purchase of the shares. Yaoming Bio has drove high in early trays, so far 5%, the turnover exceeds HK $ 500 million.

The A -share CXO sector was heated simultaneously, Yaoming Kangde, Tiger Pharmaceutical, Kang Longcheng, and Midizizi rose more than 2%. The medical sector recovered in the early early trading. Medical White Horse stocks have risen sharply, and the SCR medical index rose more than 2%.

In terms of popular ETFs, the largest medical ETF (512170) has increased by 2%as of now, with a turnover of 290 million yuan. Last week's single -week fund share increased by 1.086 billion copies, with a continuous suction of more than 490 million yuan in 5 days. In the past 20 days, the net inflow of funds was nearly 2.2 billion yuan.

According to the latest performance data, the performance of the Chinese Stock Exchange Medical Index continued to maintain a high -speed growth in the first half of 2022. The main business income growth rate of the main business of the sector was 42%according to the overall method, and the net profit growth rate was 45%. Among them, the concept of CXO was the most high. The total net profit of the 8 CXO concepts of the CSI Medical Index exceeded 10.3 billion yuan, an increase of more than 82%compared to 2021!

- END -